On April 17, 2026 Precision Biologics, Inc. reported a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing truncated core 1 O-glycans will be presented in a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting on April 19th, 2026, in San Diego, CA, USA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster title: NEO-201-recognized truncated Core 1 O-glycans represent a new target for CAR-NK therapy in AML
Presentation of the poster will be made in person on the following date and location:
Sunday, April 19th, 2:00pm – 5:00pm PT
San Diego Convention Center, San Diego, CA, USA
Exhibit Hall
Session Category: Immunology
Session Title: Alternative Cell Type and in Situ Cell Therapies
Location: Poster Section 7
Poster Board Number: 7
Poster Number: 133
Abstract Number: 7933 (published in Cancer Research: View Source)
BACKGROUND:
Acute myeloid leukemia (AML) continues to have poor long-term outcomes, particularly in high-risk and relapsed/refractory disease. Progress in AML immunotherapy has been hindered by the scarcity of antigens selectively expressed on leukemic cells while sparing hematopoietic stem/progenitor cells (HSPCs).
Recent data to be presented for the first time at AACR (Free AACR Whitepaper), clearly identifies truncated Core 1 O-glycans recognized by NEO-201 as a novel AML-associated antigen present across multiple subtypes and largely absent from early hematopoietic progenitors. The potent antileukemic activity of NEO-201CAR NK cells in preclinical systems highlights the promise of this approach and sets the stage for advancing truncated Core 1 O-glycan-directed Cellular therapies into translational and clinical development.
"What was surprising to us was this novel target originally was discovered in solid tumors not healthy tissue, but its expression is also found in hematologic cancers. This provides the basis of targeting this specific glycan when developing cellular therapies for the treatment of refractory leukemias" said Dr. Philip M. Arlen, of Precision Biologics, Inc.
With a 5-year relative survival of only 32.9% from 2015 – 2021, it’s estimated that in the US in 2025 AML claimed about 22,000 new cases, with over 11,000 deaths. (seer.cancer.gov)
(Press release, Precision Biologics, APR 17, 2026, View Source [SID1234664490])